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Abstract
Depression and depressive symptoms predict poor adherence to medical therapy, but the association is complex,
nonspecific, and difficult to interpret. Understanding this association may help to identify the mechanism explaining the
results of interventions that improve both medical therapy adherence and depressive symptoms as well as determine the
importance of targeting depression in adherence interventions. We previously demonstrated that Managed Problem
Solving (MAPS) focused on HIV medication adherence improved adherence and viral load in patients initiating a new
antiretroviral regimen. Here, we assessed whether MAPS improved depressive symptoms and in turn, whether changes in
depressive symptoms mediated changes in adherence and treatment outcomes. We compared MAPS to usual care with
respect to presence of depressive symptoms during the trial using logistic regression. We then assessed whether MAPS’
effect on depressive symptoms mediated the relationship between MAPS and adherence and virologic outcomes using
linear and logistic regression, respectively. Mediation was defined by the disappearance of the mathematical association
between MAPS and the outcomes when the proposed mediator was included in regression models. Although MAPS
participants had a lower rate of depressive symptoms (OR = 0.45, 95% confidence interval 0.21–0.93), there was no evidence
of mediation of the effects of MAPS on adherence and virological outcome by improvements in depression. Thus,
interventions for medication adherence may not need to address depressive symptoms in order to impact both adherence
and depression; this remains to be confirmed, however, in other data.
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Introduction
Adherence to antiretroviral drugs is central to HIV treatment
success, with the goal being suppression of plasma virus levels to
below the limit of quantification (i.e., ‘‘undetectable viral load’’).
Yet, non-adherence to medical therapy occurs in upward of 50%
of patients on efficacious self-administered therapies [1], resulting
in treatment failure and avoidable complications of disease.
Depressive symptoms are common among HIV infected individ-
uals [2], and a recent meta-analysis showed that depressive
symptoms are a marker for poor treatment adherence [3].
Moreover, the association was not limited to major depressive
disorder, but extended to subclinical levels of depressive symptoms
[4], leading authors of that meta-analysis to call for interventions
that focus on reducing severity of depressive symptoms even when
symptoms are at subclinical levels.
A limited literature suggests that treatment targeting both
depressive disorders and adherence with psychotherapy improves
adherence to HIV treatment [5]. For instance, a recent study
showed that Cognitive Behavioral Therapy for Adherence and
Depression in HIV-infected injection drug users improved both
depressive symptoms and adherence, but not viral loads [6].
However, causal interpretations of the effect of treating depression
on adherence outcomes are complicated by consistent findings that
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depressive symptoms are correlated with a full range of other
negative affect variables, as well physical health problems,
concurrent stress, and adjustment problems [7]. Many of these
factors are also barriers to medication adherence. Therefore,
addressing these factors directly, rather than addressing depres-
sion, may be a more direct route to improving adherence.
The pragmatic clinical issue remains whether we can afford not
to address depressive symptoms in interventions focused on
adherence and still obtain the effect on medication taking. If
depressive symptoms are a marker for poor adherence, do
improvements in depressive symptoms serve as a mediator for
improved adherence? Regardless, can a secondary reduction in
depressive symptoms be a basis for further recommending
interventions that improve adherence? Answers to these questions
have important implications for the design and dissemination of
interventions to improve adherence.
We addressed these questions by taking advantage of data from
a previously described [8] clinical trial of an HIV adherence
intervention, Managed Problem Solving (MAPS). MAPS resulted
in an average increase of 15.2% of doses taken (p,0.001) and a
1.48 (95% CI: 0.94–2.31) times greater odds for undetectable viral
load compared to usual care [8]. This face-to-face problem
solving-based counseling intervention is particularly relevant to the
question of whether reductions in depressive symptoms mediate
adherence effects because it is derived from problem-solving
therapy for depression, but it is intended to address only specific
barriers to adherence, not depression. The MAPS treatment
protocol (available at http://www.med.upenn.edu/cceb/maps-
form.shtml) specifically excludes any focus on general problem
orientation or expectancies (i.e., those problems or expectancies
beyond the focus on adherence to antiretroviral therapy or HIV
treatment outcomes) that are considered so crucial in problem-
solving therapy for depression [9]. In MAPS, when possible,
clinical depression is identified as one of the barriers to adherence,
referrals are simply offered for formal diagnosis and treatment
outside of the intervention.
In the present study, we aimed to determine whether MAPS
improved depressive symptoms, and if so, whether improvement
in depressive symptoms mediated the effect of MAPS on
adherence and virologic response, taking into account the offering
of referral for depression treatment.
Methods
We conducted a secondary analysis of a randomized clinical
trial comparing MAPS to usual outpatient HIV care in HIV
infected individuals newly starting or changing antiretroviral
regimens due to prior treatment failure or discontinuation. Details
of the MAPS trial have been previously published [8]. Briefly, we
recruited 180 patients (91 MAPS, 89 usual care) from 3 HIV
clinics in Philadelphia via word of mouth from clinicians and
pharmacists and fliers sent directly to patients. Usual care at the
sites included meeting with a pharmacist for education about the
regimen, potential side effects, and if desired, provision of pill
organizers. Exclusion criteria were inability to provide informed
consent and residence in a setting where medications were
delivered automatically.
Delivery of MAPS Intervention
Three interventionists were trained over 15 hours each
regarding HIV disease and treatment, depression and substance
abuse, and in the use of the Managed Problem Solving treatment
manual and workbooks. Interventionists were required to have a
college degree and experience working with patients.
The MAPS intervention includes 5-steps: 1)identifying partic-
ipant’s barriers to adherence, 2)brainstorming for potential
solutions, 3)selecting the best option, 4)monitoring whether it
was implemented and considered useful, and 5)monitoring the
participant’ s adherence and reiterating steps 2–4 if solutions were
either not implemented or unsuccessful. Notably, the problem
solving strategy was designed to overcome barriers to adherence,
not to improve a patient’s problem solving skills as a general means
of improving either adherence or depression. Baseline screening
for all participants was conducted by a single study coordinator
who was not one of the interventionists. The screening aided in the
identification of common potential adherence barriers, using CES-
D for depressive symptoms [10], the AUDIT [11], and ASI
questionnaires [12] for substance abuse, and a questionnaire
regarding HIV knowledge, health, and religious beliefs. If CES-D
scores were $22, participants were then asked about duration of
mood disturbance. If endorsed to be present for two weeks,
depressive symptoms were identified as a potential adherence
barrier. In the MAPS group, the interventionist focused the 5-step
process on accessing depression counseling and/or pharmacother-
apy, including a) referring the client for a psychiatric evaluation, b)
referring the client to a counseling center or treatment program; c)
asking to call their provider or having them speak to their
provider; d) having them speak to clergy; e) enlisting the support of
family or close friends, or f) offering the support of the
interventionist, depending on the patients’ preferences.
We intended for the MAPS interventionists to deliver 4 face-to-
face sessions and 12 telephone check-ins over the initial 3 months
of the study and then 9 monthly refill reminder calls for the
remainder of the year. Fidelity to the intervention was above the a
priori designated threshold in all cases based on standardized
evaluations of recorded sessions [8]. We targeted a sample size of
180 participants for at least 80% power to determine if MAPS
improved adherence by at least 10% of doses.
Measures
The CES-D was used to measure depressive symptoms
quarterly for one year [10]. A cutoff of 22 was a priori designated
to be consistent with depression rather than the usual cutoff of 16
because in a primary care setting, an elevated CES-D has
moderate specificity, but low (,35%) positive predictive value, still
necessitating a clinical inquiry to determine if treatable depression
is present [13]. We also included CES-D score as a continuous
measure in further analyses, because of concerns expressed in the
literature that dichotomization loses information and increases the
risk of Type II error [14,15].
Adherence was measured over time using electronic monitors
(MEMS, Aardex, Switzerland) and summarized as proportion of
doses taken over each quarter for one year. Plasma HIV-1 RNA
concentration was measured quarterly over 1 year with an assay
having a lower limit of 75 copies/ml (Versant, HIV-1 RNA 3.0,
Bayer Corp. Berkeley, CA).
We also assessed participants with CES-D scores $22 with
respect to whether they sought treatment for depression including
counseling and/or antidepressant medications.
Analysis
The focus of these analyses was to compare the experimental
and control groups for the presence of depressive symptoms over
time and determine whether these symptoms mediated the effect
of MAPS on adherence and virologic suppression. We used an
intention-to-treat approach to compare the presence of depressive
symptoms over time between the MAPS and usual care groups.
We estimated the association between study group and differences
Relation of Depression Change and Adherence Change
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in CES-D score and CES-D score$22 over all four quarters of the
year using generalized estimating equations (GEE) with linear
regression and logistic regression for the respective outcomes [16].
Individuals who were lost to follow-up were included as having
virologic failure at all subsequent time points [17]. In secondary
analyses, we tested for potential confounding by measured
variables by including covariates in the GEE models and
inspecting for changes in the point estimate of the relation
between study group and outcome. Potential confounders
included baseline CES-D score$22, race, sex, and age. We also
tested for effect modification by time including an interaction term
(MAPS x time point) in the models.
We assessed whether improvements in depressive symptoms
mediated the effect of MAPS in separate GEE models for the
outcomes of adherence and virologic suppression. We used the
values from the primary analyses of the effect of MAPS on
adherence as the base case. We included percent of doses taken
over each quarter as a continuous variable and modeled the
relation between MAPS and adherence using linear regression.
We then added presence of high-level depressive symptoms for
each participant at each time point into the models. We then
compared the point estimate of the effect of MAPS on the
outcome between the models with and without depression. We
then repeated these analyses for the outcome of viral suppression,
but using logistic regression instead of linear regression. We
interpreted changes in the point estimate of the relation between
the intervention and outcomes toward 1 as evidence of mediation.
In addition, we assessed whether changes in depressive symptoms
within the individual over time were associated with changes in
that individual’s adherence over time. Specifically, we calculated
the change in CES-D score over each interval and assessed the
association with adherence in the subsequent interval using linear
regression with GEE.
We then tested whether baseline elevated CES-D scores
modified the effect of MAPS on later depressive symptoms by
including an interaction term (intervention group x baseline CES-
D.22) in the GEE models.
In order to determine the effect of MAPS on patients with high
levels of depressive symptoms obtaining mental health care, we
compared the proportion of individuals in the MAPS and usual
care arms with CES-D scores.22 with respect to the proportion
seeking treatment of depression and taking antidepressant
medications during the course of the study using Chi-squared
and Fisher’s exact tests.
Ethical Considerations
We obtained written informed consent from all participants.
The study was approved by the Committee on Human Subjects
Research of the University of Pennsylvania and the Philadelphia
Veterans Affairs Medical Center. Participants were compensated
$30 per data collection visit, but not intervention visits. There were
no early stopping rules. The ClinicalTrials.gov number is
NCT00130273.
Results
Depressive symptoms were common with 41 participants
meeting the threshold of CESD$22 at baseline; 19 (21%) in
MAPS and 22 (25%) in usual care arms, respectively. Table 1
displays differences between those with and without baseline CES-
D score$22. Higher CES-D scores were associated with being
female, hazardous alcohol use, being unemployed, and having low
income, although none of these differences were statistically
significant. MAPS was associated with a 2.3 point lower CES-D
score across all time points (p = 0.046).
Table 2 depicts the various models of the association between
MAPS and high-level depressive symptoms (CES-D score$22) at
each quarter of follow-up. When time point was included as a
potential confounder in the models, there was no change in the
point estimate or 95% CI of the relation between MAPS and
presence of high-level depressive symptoms. Further, there was no
evidence of effect modification by time on the relation between
MAPS and high-level depressive symptoms (MAPS x time point
interaction term p value = 0.99). Although the 95% confidence
intervals cross 1 at each time point, MAPS was associated with a
lower proportion of participants with high-level depressive
symptoms throughout the study. In the unadjusted model, MAPS
was associated with a decreased odds of depressive symptoms over
time. In addition, there was no association between change in
depressive symptoms over each interval and change in adherence
Table 1. Baseline Characteristics by Depressive Symptoms.
Characteristic CESD$22 (n =41) CESD,22 (n =137) p value
Study group
MAPS 19 (21%) 72 (79%) 0.49
Usual Care 22 (26%) 65 (71%)
Median Age (Interquartile range) 43 (39–49) years 43 (35–51) .0.5
Female sex 21 (51%) 50 (37%) 0.09
Race
Black 33 (80%) 118 (86%) 0.29
White 8 (20%) 16 (12%)
Other 0 3 (2%)
Income,$5000/yr 18 (44%) 39 (29%) 0.06
Hazardous Alcohol use 11 (27%) 21 (15%) 0.09
History of injection drug use 9 (22%) 20 (15%) 0.26
Currently employed 4 (10%) 31 (23%) 0.07
HIV Treatment naı¨ve 19 (46%) 53 (39%) 0.38
doi:10.1371/journal.pone.0084952.t001
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over each subsequent interval. For every 1 point increase in
depressive symptoms over time, adherence decreased by 0.1% of
doses taken, p = 0.4.
Table 3 displays the analyses assessing for potential confounders
or mediators. Baseline CES-D score$22 did not confound the
protective effect of MAPS. In the mediation analyses, again, there
was no effect of including either adherence or virologic
suppression in the models. Nor was there evidence that the effect
of MAPS on depressive symptoms differed between those with and
without baseline CESD score$22 (p value for interaction between
MAPS and baseline CESD score = 0.45.
There was no evidence that depressive symptoms mediated the
effect of MAPS on either adherence (increase of 15.9% of doses
taken, p = 0.0015) or virologic suppression (OR 1.72 (95% CI
1.00–3.00), with the point estimates remaining significant and not
decreasing from the unadjusted models for these outcomes.
The proportion of individuals who sought counseling for
depression was similar between the groups, 18/91 (20%) in the
MAPS arm and 25/89 (28%) in the usual care arm (p = 0.19). The
majority were seen by psychiatrists, 17 (94%) in MAPS and 21
(84%) in usual care (p = 0.38). Antidepressants were prescribed for
13 (72%) MAPS participants and 21 (84%) usual care participants
(p = 0.35). These results suggest that MAPS did not have its effect
on depressive symptoms merely by increasing the referral and
treatment of depression by other providers.
Discussion
We found that a problem-solving based intervention, MAPS, to
be effective not only at improving adherence and virologic
suppression as shown previously [8], but also at improving
depressive symptoms. The improvement in depressive symptoms
was not different over the different time points and was not
confounded by any of the measured factors. The lack of
association between change in depression symptoms and change
in adherence over time and the lack of change in the point
estimate of the association between MAPS and the outcomes when
depression was included in the models both suggest that the effect
of MAPS on adherence was not mediated by its effect on
depression.
The lack of increase in use of services for depression by
participants with high CES-D scores also suggests that specific
MAPS activities did not directly impact receipt of care for
depression. Further data indicate that among patients in regular
contact with the medical system because of management of a life-
threatening chronic condition, rates of prescription of antidepres-
sants are high [18,19], but quality of care for depression may be
low because of subordination of the goal of treating depression to
the competing demand for adequately managing the chronic
illness [20]. Rather than leaving this complex issue to speculation,
future research should ascertain the specificity with which
antidepressants are prescribed to patients in treatment for HIV
and the quality of depression care. The MAPS group received
more in-person visits and telephone calls throughout the year than
the control group, by nature of the intervention. These visits may
have resulted in improvements in depressive symptoms, but these
visits only occurred over the first 3 months of the study. The visits
between the experimental and usual care subjects were equal over
the remainder of the year. This added contact may have been
responsible for the improvement in depressive symptoms, since
referrals for treatment did not differ between the groups.
Observational studies have suggested that treatment of depres-
sion would result in improved treatment adherence[21–23].
However, a recent study of directly observed fluoxetine to treat
depression in HIV resulted in improvements in depressive
symptoms, but no change in HIV treatment outcomes. [24]
Similarly, a trial of a cognitive behavioral therapy intervention for
adherence and depression in HIV infected individuals resulted in
improved adherence and depressive symptoms, yet only the
improvement in depressive symptoms persisted after the interven-
tion was discontinued [6]. The lack of association between
improvements in depression and improvements in adherence in
these two intervention studies targeting depression is consistent
with our observation that improvement in depressive symptoms
does not mediate improvement in adherence.
Even if MAPS does not directly address depressive symptoms,
there may be important nonspecific elements of the interaction
between MAPS interventionists and patients that serve to reduce
these symptoms. The MAPS intervention involves regular contact
with a supportive interventionist who inquires about patients’
Table 2. Effect of MAPS on CESD Score.22 at Each Time Point.
Time Point Odds Ratio (95% CI) for Presence of CESD Score$22 in MAPS vs. UC
Month 3 0.46 (0.17–1.20)
Month 6 0.41 (0.13–1.31)
Month 9 0.42 (0.16–1.15)
Month 12 0.47 (0.16–1.37)
doi:10.1371/journal.pone.0084952.t002
Table 3. Assessment of Potential Confounding or Mediation of the Relation between MAPS and CES-D Score$22 Over Time.
Variables included in model Odds Ratio (95% CI) for Presence of CESD Score$22
MAPS vs. UC (Base case) 0.44 (0.21–0.93)
MAPS vs UC+Baseline CESD Score.22 0.50 (0.23–1.10)
MAPS vs. UC+Adherence over Time 0.55 (0.24–1.26)
MAPS vs. UC+Virologic Suppression over Time 0.50 (0.24–1.10)
doi:10.1371/journal.pone.0084952.t003
Relation of Depression Change and Adherence Change
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management of their HIV regimen and collaborates in solving a
problem the interventionist and patients negotiate. Interventionists
were trained to focus on adherence barriers per se, but were also
trained to build rapport by listening sympathetically to other issues
participants raised. Because the interventionist has less of a history
or external incentives for insisting upon patients’ adherence, the
interventionist is in a position to be less blaming and critical than
patients’ providers may become. Thus, they may positively
influence adherence without the negative affective impact that
more critical providers may engender. To test whether these
speculations about nonspecific influences in the MAPS interven-
tion are true, future trials might seek to accentuate supportive
accountability [25], rather than attempting to control for it, and
examine their secondary effect on depressive symptoms, as well as
the primary outcomes of medication adherence and viral loads.
This study has several potential limitations. Although we
measured depressive symptoms, we did not determine whether
these symptoms represented a clinical diagnosis of depression or
more diffuse distress. With the standard cutoff $16, the CES-D
has been found to have a sensitivity of 79.5% and a specificity of
71.1% for major depression [26]. We used a higher cutoff of $22,
which would increase the positive predictive value, but most
patients with scores above this cut point would likely still not meet
diagnostic criteria for clinical depression. Yet, the median CES-D
score was quite high in this sample, increasing the likelihood that if
depressive symptom improvement mediated the outcomes, we
would have identified it. Although this was only a single-blinded
study, the CES-D was administered by staff who were not part of
the intervention team to decrease the likelihood of biased
reporting of depressive symptoms. In general, receipt of a
prescription for antidepressants was high in both the intervention
and control group members with high CES-D scores, but we have
no data concerning why patients chose their mode of mental
health care, or the effectiveness, appropriateness, or quality of this
treatment. We also did not assess use of services by patients with
lower CES-D scores and therefore cannot comment on MAPS
effect on seeking of mental health care by participants with lower
levels of distress. Furthermore, as a real-world intervention,
participants in the experimental arm did not universally adhere
to the protocol [8]. Yet even despite imperfect implementation, the
intervention still improved depressive symptoms. Thus, it is
possible that we are underestimating the strength of the effect of
MAPS on depressive symptoms.
This study has several strengths. It was conducted as a
randomized trial, which controls for known and unknown
confounders of the relation between the intervention and
outcomes. Objective outcome measures were included-adherence
via microelectronic monitors and treatment success via HIV viral
loads. Further, depressive symptoms were followed serially over 1
year allowing assessment of the effect over time.
In conclusion, we found that a problem solving-based adher-
ence intervention improved depressive symptoms, but did so
independent of its effect on adherence and biological outcomes.
Future modifications to adherence interventions such as MAPS
may not need to be targeted to depressive symptoms to have an
effect on adherence in a highly symptomatic population. This
hypothesis warrants testing in further trials of medication
adherence interventions.
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